Related Experiment Video
Updated: Aug 21, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Screening for cancer: valuable or not?
1Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California at Irvine, 101 The City Drive, Building 56, Room 215, Route 81, Orange, CA 92868, USA. flmeyske@msx.ndc.mc.uci.edu
Abstract:
Screening for cancer has become extremely common. The evidence supporting screening for breast, colon, and cervix cancer is strong, but it is unclear for skin cancer, problematic for prostate cancer, and ineffective for lung cancer. Despite the problems associated with many screening approaches for cancer, enthusiasm by the medical profession and the public remains high. The objective analysis for the major tumor types is presented in this review, but the ultimate decision on whether to be screened lies in the personal and societal arena of values.
Related Concept Videos
Preventive Healthcare Services
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
